In both cases, the relative risks of breast cancer in BARD1 variant carriers were unchanged and the significance of the findings was maintained (p = 0.032 and 0.023 when adjusted for contemporary patients' geographical origins and the origins of the fifth-generation ancestors, respectively). This evidence concerns the gene BARD1 and breast carcinoma.